Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Biote (BTMD) EBITDA (2021 - 2025)

Biote has reported EBITDA over the past 5 years, most recently at $27.5 million for Q4 2025.

  • Quarterly results put EBITDA at $27.5 million for Q4 2025, up 198.76% from a year ago — trailing twelve months through Dec 2025 was $36.0 million (up 329.81% YoY), and the annual figure for FY2025 was $31.6 million, up 101845.16%.
  • EBITDA for Q4 2025 was $27.5 million at Biote, up from $8.5 million in the prior quarter.
  • Over the last five years, EBITDA for BTMD hit a ceiling of $27.5 million in Q4 2025 and a floor of -$85.3 million in Q2 2022.
  • Median EBITDA over the past 5 years was $7500.0 (2022), compared with a mean of -$2.5 million.
  • Biggest five-year swings in EBITDA: tumbled 852980.0% in 2022 and later surged 400.0% in 2025.
  • Biote's EBITDA stood at $6.1 million in 2021, then rose by 24.54% to $7.6 million in 2022, then plummeted by 403.88% to -$23.1 million in 2023, then fell by 20.55% to -$27.9 million in 2024, then soared by 198.76% to $27.5 million in 2025.
  • The last three reported values for EBITDA were $27.5 million (Q4 2025), $8.5 million (Q3 2025), and $9000.0 (Q2 2025) per Business Quant data.